Kai-Cheng Hsu

Nov 13, 2024 | journals.plos.org | Kai-Cheng Hsu |Hui-Chen Hung |Jim-Tong Horng |Ming-Yu Fang

The affiliation for the ninth author is incorrect. Ding-Li Chou is not affiliated with #3 but with #4: Department of Biological Science and Technology, National Chiao Tung University, Hsinchu, Taiwan. Reference1. Hsu K-C, Hung H-C, Horng J-T, Fang M-Y, Chang C-Y, Li L-T, et al. (2013) Parallel Screening of Wild-Type and Drug-Resistant Targets for Anti-Resistance Neuraminidase Inhibitors. PLoS ONE 8(2): e56704.

Jul 19, 2024 | mdpi.com | Hung-Yu Lin |Kai-Cheng Hsu |Yu-Ming Hsu |Tsen-Ni Tsai

All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.

May 9, 2024 | onlinelibrary.wiley.com | Cheng-Chiao Huang |Chia-Ming K. Hsu |Min-Wu Chao |Kai-Cheng Hsu

1 INTRODUCTION Breast cancer (BC) is the most common cancer among women globally, and its incidence continues to rise annually. BC can be categorized based on the expression status of the estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2). Remarkable progress has been made in developing targeted therapies for these biomarkers, significantly improving both patient survival rates and progression-free survival.

Mar 14, 2024 | nature.com | Ming-Jer Young |Shao-An Wang |Chia-Yu Liu |Kai-Cheng Hsu |Yi-Ching Wang |Yung-Ching Chen | +1 more

AbstractDrug resistance in cancer therapy is the major reason for poor prognosis. Addressing this clinically unmet issue is important and urgent. In this study, we found that targeting USP24 by the specific USP24 inhibitors, USP24-i and its analogues, dramatically activated autophagy in the interphase and mitotic periods of lung cancer cells by inhibiting E2F4 and TRAF6, respectively.

Sep 15, 2023 | nature.com | Kuan-Jen Lu |Chiung-Wen Chang |Chun-Hsiung Wang |Frederic Y-H Chen |Irene Huang |Cheng-Han Yang | +4 more

Correction to: Nature Metabolism https://doi.org/10.1038/s42255-023-00831-w, published online 22, June 2023. In the version of this article originally published, panels b–k of Figure 6 were inadvertently mislabeled. Aside from the panel labels, the figure has not been changed, and the descriptions in the text and the legend are not affected. The errors have been corrected in the HTML and PDF versions of the article.